Literature DB >> 20685766

Characteristic brain magnetic resonance imaging abnormalities in central nervous system aquaporin-4 autoimmunity.

Woojun Kim1, Min Su Park, Sang Hyun Lee, Su-Hyun Kim, In Ja Jung, Toshiyuki Takahashi, Tatsuro Misu, Kazuo Fujihara, Ho Jin Kim.   

Abstract

BACKGROUND: Although neuromyelitis optica has been traditionally regarded as a disease without brain involvement, brain abnormalities are not uncommon in patients with neuromyelitis optica-related disorders.
METHODS: We aimed to characterize the brain magnetic resonance imaging (MRI) abnormalities in neuromyelitis optica spectrum disorder patients who are seropositive for anti-aquaporin-4 autoantibody (AQP4 Ab). Of 236 consecutive patients with inflammatory demyelinating central nervous system diseases, we retrospectively analyzed MRI characteristics of 78 patients who were seropositive for AQP4 Ab.
RESULTS: For an average observational period of 6.3 years, 62 patients (79%) had brain lesions on MRI. Twenty-four patients (31%) had brain MRI abnormalities at the onset of disease, and 35 (45%) had symptomatic brain involvement. Characteristic brain MRI abnormalities were classified into five categories: (1) lesions involving corticospinal tracts (e.g. posterior limb of internal capsule and cerebral peduncle (44%); (2) extensive hemispheric lesions likely due to vasogenic edema (29%); (3) periependymal lesions surrounding aqueduct and the third and fourth ventricles (22%); (4) periependymal lesions surrounding lateral ventricles (40%); and (5) medullary lesions, often contiguous with cervical lesions (31%). Fifty-four patients (69%) showed at least one kind of brain abnormality among the five characteristic MRI lesions. Ten patients showed gadolinium-enhancing lesions, which were characterized by multiple patchy enhancing patterns with blurred margins.
CONCLUSIONS: In central nervous system AQP4 autoimmunity, brain MRI abnormalities were more common than is generally appreciated and were characterized by their unique localization and configuration.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20685766     DOI: 10.1177/1352458510376640

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  48 in total

1.  AQP4 antibody-positive Thai cases: clinical features and diagnostic problems.

Authors:  S Siritho; I Nakashima; T Takahashi; K Fujihara; N Prayoonwiwat
Journal:  Neurology       Date:  2011-08-03       Impact factor: 9.910

Review 2.  Common and Rare Manifestations of Neuromyelitis Optica Spectrum Disorder.

Authors:  Dominique Rosales; Ilya Kister
Journal:  Curr Allergy Asthma Rep       Date:  2016-06       Impact factor: 4.806

3.  Racial differences in neuromyelitis optica spectrum disorder.

Authors:  Su-Hyun Kim; Maureen A Mealy; Michael Levy; Felix Schmidt; Klemens Ruprecht; Friedemann Paul; Marius Ringelstein; Orhan Aktas; Hans-Peter Hartung; Nasrin Asgari; Jessica Li Tsz-Ching; Sasitorn Siritho; Naraporn Prayoonwiwat; Hyun-June Shin; Jae-Won Hyun; Mira Han; Maria Isabel Leite; Jacqueline Palace; Ho Jin Kim
Journal:  Neurology       Date:  2018-10-26       Impact factor: 9.910

Review 4.  The current role of MRI in differentiating multiple sclerosis from its imaging mimics.

Authors:  Ruth Geraldes; Olga Ciccarelli; Frederik Barkhof; Nicola De Stefano; Christian Enzinger; Massimo Filippi; Monika Hofer; Friedemann Paul; Paolo Preziosa; Alex Rovira; Gabriele C DeLuca; Ludwig Kappos; Tarek Yousry; Franz Fazekas; Jette Frederiksen; Claudio Gasperini; Jaume Sastre-Garriga; Nikos Evangelou; Jacqueline Palace
Journal:  Nat Rev Neurol       Date:  2018-03-09       Impact factor: 42.937

5.  Brain MRI Findings in Pediatric-Onset Neuromyelitis Optica Spectrum Disorder: Challenges in Differentiation from Acute Disseminated Encephalomyelitis.

Authors:  E Bulut; J Karakaya; S Salama; M Levy; T A G M Huisman; I Izbudak
Journal:  AJNR Am J Neuroradiol       Date:  2019-03-07       Impact factor: 3.825

6.  [Diagnosis and treatment of neuromyelitis optica. Consensus recommendations of the Neuromyelitis Optica Study Group].

Authors:  C Trebst; A Berthele; S Jarius; T Kümpfel; S Schippling; B Wildemann; C Wilke
Journal:  Nervenarzt       Date:  2011-06       Impact factor: 1.214

Review 7.  Neuromyelitis Optica Spectrum Disorders (NMOSD) and Connective Tissue Disease (CTD): an Update for the Rheumatologist.

Authors:  Roberto A Cruz; Sana Chaudhary; Myriam Guevara; Ethan Meltzer
Journal:  Curr Rheumatol Rep       Date:  2021-04-28       Impact factor: 4.592

Review 8.  What do we know about brain contrast enhancement patterns in neuromyelitis optica?

Authors:  Yeliz Pekcevik; Gunes Orman; In Ho Lee; Maureen A Mealy; Michael Levy; Izlem Izbudak
Journal:  Clin Imaging       Date:  2015-07-26       Impact factor: 1.605

Review 9.  Differential diagnosis of white matter lesions: Nonvascular causes-Part II.

Authors:  S Weidauer; M Nichtweiss; E Hattingen
Journal:  Clin Neuroradiol       Date:  2014-02-12       Impact factor: 3.649

Review 10.  Conventional and advanced imaging in neuromyelitis optica.

Authors:  Y Barnett; I J Sutton; M Ghadiri; L Masters; R Zivadinov; M H Barnett
Journal:  AJNR Am J Neuroradiol       Date:  2013-06-13       Impact factor: 3.825

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.